Bullfrog AI (NASDAQ:BFRG) vs. Genelux (NASDAQ:GNLX) Critical Review

Bullfrog AI (NASDAQ:BFRG) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for Bullfrog AI and Genelux, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bullfrog AI	0	0	0	0	N/A
Genelux	0	0	4	0	3.00

Genelux has a consensus target price of $32.33, suggesting a potential upside of 1,469.58%. Given Genelux’s higher probable upside, analysts clearly believe Genelux is more favorable than Bullfrog AI.

Insider and Institutional Ownership

1.0% of Bullfrog AI shares are owned by institutional investors. Comparatively, 37.3% of Genelux shares are owned by institutional investors. 11.7% of Genelux shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Bullfrog AI and Genelux’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bullfrog AI	$60,000.00	237.46	-$5.36 million	($0.88)	-2.06
Genelux	$170,000.00	416.24	-$28.30 million	($0.97)	-2.12

Bullfrog AI has higher earnings, but lower revenue than Genelux. Genelux is trading at a lower price-to-earnings ratio than Bullfrog AI, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Bullfrog AI has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500. Comparatively, Genelux has a beta of -1.37, suggesting that its stock price is 237% less volatile than the S&P 500.

Profitability

This table compares Bullfrog AI and Genelux’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bullfrog AI	N/A	-131.39%	-114.76%
Genelux	N/A	-125.58%	-86.03%

Summary

Genelux beats Bullfrog AI on 8 of the 12 factors compared between the two stocks.

About Bullfrog AI

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.